Ixekizumab Gets FDA Nod for Active Psoriatic Arthritis
Psoriatic arthritis is the second approved indication for Taltz in the United States.
Stopping Bisphosphonates Ups Hip Fracture Risk
Study findings may help guide rheumatologists plan long-term therapy for patients dealing with low bone mass.
In Lupus, Low Vitamin D Means High Renal Disease Risk
There’s a higher risk of total organ damage and end-stage renal disease in patients with SLE.
Golimumab FDA Approved for Psoriatic Arthritis, Ankylosing Spondylitis
This is the only fully human anti-TNF-α infused therapy approved for psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis.
Arthritis Advocates Call on Congress
Rheumatology leaders prescribe legislative fixes for drug cost and access issues.
Arthritis Tracking Web and Mobile App Hits Recruitment Mark
The first patient-led, patient-centered research registry for joint, bone, and inflammatory skin conditions enrolls 11,000 patients.
Rheumatoid Arthritis Has Unseen Symptoms, Survey Says
A majority of patients said they found it difficult to explain the “invisible” aspects to others.
Psoriasis Severity Tied to Death Risk
This study was the first to use an objective measure to link severity of psoriasis and risk of death.
Ibuprofen Elevates Blood Pressure in Arthritis
Hypertension goes up more than with celecoxib in patients who are at increased risk for cardiovascular disease.
Duzallo Gains FDA Nod for Hyperuricemia in Uncontrolled Gout
This is the first FDA-approved fixed-dose combination treatment that addresses both overproduction and underexcretion of serum uric acid in a single pill.